Alleviate-HF-2 Study

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 3, 2021

Primary Completion Date

September 1, 2023

Study Completion Date

December 31, 2023

Conditions
Heart Failure
Interventions
DEVICE

ALV1 System

The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.

Trial Locations (5)

Unknown

Flinders Medical Centre, Adelaide

Monash Medical Centre, Clayton

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

Southern District Health Board, Dunedin

Karolinska University Hospital, Stockholm

Sponsors
All Listed Sponsors
lead

Alleviant Medical, Inc.

INDUSTRY

NCT04838353 - Alleviate-HF-2 Study | Biotech Hunter | Biotech Hunter